

CURRICULUM VITAE

December, 2014

Name: Joanna H. Shih**Office Address:**

National Cancer Institute
 Biometric Research Branch, DCTD
 9609 Medical Center Drive, Rm 5W124, MSC 9735
 Bethesda, Maryland 20892
 (240) 276 - 6035 (office)
 (240) 276 - 7888 (fax)
 jshih@mail.nih.gov

Home Address:

25 Farm Haven Court
 Rockville, MD 20852
 (301) 881-8272
 shih.jh@gmail.com

Education:

- 1992 Ph.D. University of Minnesota, Minneapolis, Minnesota
 Major: Biostatistics
 Thesis advisor: Thomas A. Louis
- 1984 M.S. University of Minnesota, Minneapolis, Minnesota
 Major: Statistics
- 1981 B.A. National Cheng-Chi University (graduated first in a class of 55 students)
 Major: Statistics

Professional Experience:

- 1981 – 1982 *Teaching Assistant.* National Cheng-Chi University
- 1982 – 1984 *Teaching Assistant.* University of Minnesota, Department of Statistics, Minneapolis, Minnesota
- 1984 – 1985 *Statistician, Tor Dahl & Associates*
- 1985-1988 *Statistical Analyst,* Division of Epidemiology, University of Minnesota, Minneapolis, Minnesota
- 1988 – 1991 *Research Assistant.* Coordinating Centers for Biostatistics Research, University of Minnesota, Minneapolis, Minnesota
- 1991 – 1992 *Research Associate.* Coordinating Centers for Biostatistics Research, University of Minnesota, Minneapolis, Minnesota. Collaborated with investigators on associating the risk factors with cardiovascular diseases from the data collected from the Multiple Risk Factors in Cardiovascular Disease study, designed AIDS clinical trials, and conducted statistical research with application to clinical trials.
- 1992 – 2001 *Mathematical Statistician.* NHLBI/NIH, Office of Biostatistics Research. Responsible for providing technical assistance and review to Program Staff on the selection of contracts for Data Coordinating Centers, including development and specification of the work scope and technical oversight. Provided technical direction in the application of statistical methodology to clinical trials. Supported program staff designing and monitoring clinical trials. Collaborated with NHLBI investigators in the design and analysis of heart disease

studies. Conducted independent statistical research in clinical trials, and health and epidemiological fields.

2001 – Present *Mathematical Statistician*. NCI/NIH, Biometric Research Branch, Division of Cancer Treatment and Diagnosis. Collaborating with investigators in Center for Cancer Research (CCR), NCI on the design and analysis of genomic studies and clinical studies in the area of radiation oncology, neuro oncology, pediatric oncology, molecular imaging, urologic oncology and medical oncology. Conduct independent research in the development of new methodologies and techniques in mathematical and/or applied statistics applicable to cancer research and related studies.

Honors and Awards:

University of Minnesota, Graduate school fellowship, 1991

Biometric Society (ENAR) John Van Ryzin Best Student Paper Award, prize competition for student papers presented at Biometric Society (ENAR) Spring Meetings, Houston, Texas, March 1991

Delta Omega Honorary Public Health Society, 1992

Teaching award, Center for Information Technology, National Institutes of Health, 2006

Fellow of the American Statistical Association, May 2007

Professional Societies:

American Statistical Association

Biometric Society

International Chinese Statistical Association

Professional Activities:

Editorship:

1999 – 2003	<i>Associate Editor, Controlled Clinical Trials</i>
2000 – 2001	<i>Associate Editor, Lifetime Data Analysis</i>
2006 – Present	<i>Associate Editor, Statistics in Medicine</i>
2008 – 2010	<i>Associate Editor, Statistica Sinica</i>
2012 – Present	<i>Associate Editor, Journal of the American Statistical Association, Application & Case Studies</i>

Elected Officer:

2004 – 2005	<i>Treasurer, Biometric Society (ENAR)</i>
2009 – 2011	<i>Member, Biometric Society (ENAR) Regional Committee Board</i>

Committee Appointments:

1995	<i>Member, ENAR Spring Meeting Program Committee</i>
1999	<i>Member, ENAR Student Paper Award Committee</i>
2002	<i>Member, ENAR Education Advisory Committee</i>
2002	<i>Program Chair, ENAR 2002 Spring Meeting, Washington D.C.</i>

2002-2004 *Member, ENAR Regional Advisory Board*
 2003-2005 *Member, American Statistical Association Committee on Meetings*

Organizing Invited Sessions:

1995 Organizer and Chair of the invited session entitled “Analysis of Multivariate Survival Data“, ENAR Spring Meeting, Birmingham, Alabama
 2002 Organizer of the invited session entitled “Recent Advances in Estimating Diagnostic Error Without a Gold Standard“, ENAR Spring Meeting, Washington D.C.
 2006 Organizer of the invited session entitled “Recent Advances in the analysis of association for multivariate failure time data“, ENAR Spring Meeting, Tampa, Florida

Teaching Experience:

Lectures:

1996-2001 Lectures on survival analysis in Core Curriculum in Clinical Research course, National Institute of Health.
 1998 Basic principles of survival analysis, National Heart, Lung and Blood Institute.

Short Courses:

2002-2010 Statistical analysis of gene expression microarray data, National Institute of Health.

Mentoring Post-doc Fellows:

2001-2005 Aleksandra M. Michalowska
 2003-2005 Huaitian Liu

Data Safety and Monitoring Board:

2000-2007 Member, hematology intramural Data and Safety Monitoring Board, National Heart, Lung and Blood Institute (NHLBI)
 2010-Present Member, NIAID Hematopoietic Stem Cell Transplant Data Safety Monitoring Board

Journal Reviewer: Statistics in Medicine, Biometrics, Biometrika, Biostatistics, Biometrical Journal, Journal of the Royal Statistical Society Series B, Statistica Sinica, Journal of the American Statistical Association, Controlled Clinical Trials, Lifetime Data Analysis, Journal of Statistical Computation and Simulation, Computational Statistics and Data Analysis, Annals of Applied Statistics, Bioinformatics, Breast Cancer Research, American Journal of Epidemiology

External Grant Review:

Reviewer for NIAID, 1997
 Reviewer for US-Israel Binational Science Foundation, 2001

Reviewer for Academia Sinica, 2010

Review for Tenure and Promotion:

National Cancer Institute, 2002, 2004, 2006
 Rutgers University, Department of Biostatistics, 2006
 University of Virginia, School of Medicine, 2009, 2011
 Emory University, Department of Biostatistics, 2013

Internal Committees at NCI:

Steering Committee member, Mouse Models of Mammary Cancer Collective, 2003-2005

Major Committees of Clinical Trials:

1993-2001	Member, T-cell Depletion Trial (TCD), National heart, Lung and Blood Institute
1994-2001	Member, Steering Committee, Atrial Fibrillation follow-up Investigation of Rhythm Management (AFFIRM) Study, National Heart, Lung and Blood Institute
1994-2001	Member, Activity Counseling Trial (ACT), National Heart, Lung, and Blood Institute
1998-2001	Member, Steering Committee, Mode Selection Trial (MOST), National Heart, Lung, and Blood Institute
1999-2001	Member, Steering Committee, Multi-ethnic study of Atherosclerosis (MESA) Study, National Heart, Lung, and Blood Institute
1999-2001	Member, Steering Committee, Feasibility of Tetinoid Therapy for Emphysema (FORTE) Clinical Trial, National Heart, Lung, and Blood Institute

Peer Reviewed Publications:

1. Stamler, J, Neaton, J, Wentworth, D, **Shih, J**, Dyer, A, Shekelle, R, Stamler, R. Life styles and life style-related major risk factors: their combined impact in producing epidemic cardiovascular disease, and the potential for prevention. *Multiple Risk Factors in Cardiovascular Disease* edited by Chobanian, A, Gotto, A, Lenfant, C, Paoletti, R, Zanchetti, A, 1991.
2. Neaton, J, Blackburn, H, Jacobs, D, Kuller, Lee, D, Sherwin, R, **Shih, J**, Stamler, J, Wentworth, D Serum cholesterol and mortality: findings for men screened in the Multiple Risk Factor Intervention Trial. *Archives of Internal Medicine* 152: 1490-1500, 1992.
3. Flack, J, Neaton, J, Grimm, R, **Shih, J**, Cutler, J, Ensrud, K, McMahon, S. Blood pressure and mortality among men with prior myocardial infarction. *Circulation* 92: 2437-2445, 1992.
4. **Shih, JH** and Louis, TA. Assessing gamma frailty models for clustered failure time data. *Lifetime Data Analysis* 1: 205-220, 1995.
5. **Shih, JH**. Sample size calculation for complex clinical trials with survival time endpoints. *Controlled Clinical Trials* 16: 395-407, 1995.

6. **Shih, JH** and Louis, TA. Inferences on the association parameter in copula models for bivariate survival data. *Biometrics* 51: 1384-1399, 1995.
7. **Shih, JH** and Louis, TA . Tests of independence for bivariate survival data. *Biometrics* 52: 1440-1449, 1996.
8. Dugi, KA, Feuerstein, IM, Hill, S, **Shih, JH**, SantamarinaFojo, S, Brewer HB Jr, Hoeg, JM. Lipoprotein lipase correlates positively and hepatic lipase inversely with calcific atherosclerosis in homozygous familial hypercholesterolemia. *Arteriosclerosis, Thrombosis, and Vascular Biology* 17: 354-364, 1997
9. Wyse DG, Anderson JL, Antman EM, Cooper ES, Dalquist JE, Davis KB, Greene HL, Mickel MC, Dimarco JP, Domanski MJ, Rosenbert Y, Schron EB, **Shih JH**, Epstein AE, Gersh BJ, Jenkins LS, Saksena S, Sherman DG, Steinberg JS, Waldo AL. Atrial fibrillation follow-up investigation of rhythm management – The AFFIRM study design. *American Journal of Cardiology* 79: 1198-1202, 1997.
10. Blair, SN, Applegate, WB, Dunn, AL, Ettinger, WH, Haskell, WL, King, AC, Morgan, TM, **Shih, JH**, and Simons-Mortan, D.G. (1998). Activity Counseling Trial (ACT): Rationale, Design, and Methods. *Medicine and Science in Sports and Exercise* 30: 1097-1106, 1998.
11. **Shih, JH**. A goodness-of-fit test for association in a bivariate survival model. *Biometrika* 85: 189-200, 1998.
12. Fay, MP, **Shih, JH**. Permutation tests using estimated distribution functions. *Journal of the American Statistical Association* 93: 387-396, 1998.
13. **Shih, JH**. Modeling multivariate discrete failure time data. *Biometrics* 54: 330-343, 1998.
14. **Shih, JH** and Fay, MP. A class of permutation tests for stratified survival data. *Biometrics* 55: 1156-1161, 1999.
15. **Shih, JH** and Albert, PS. Latent model for correlated binary data with diagnostic error. *Biometrics* 55: 1232-1235, 1999.
16. Mohiddin, SA, Begley, D, **Shih, JH**, Fananapazir, L. Myocardial bridging does not predict sudden death in children with hypertrophic cardiomyopathy but is associated with more severe cardiac disease. *Journal of American College of cardiology* 36:2270-2278, 2000.
17. Chatterjee, N, **Shih, JH**, Hartge, P, Brody, L, Tucker, M, Wacholder, S. Association and aggregation analysis using kin-cohort designs with applications to genotype and family history data from the Washington Ashkenazi Study. *Genetic Epidemiology* 21: 123-138, 2000.
18. Fananapazir, L, Mohiddin, SA, Begley, D, **Shih, JH** (2001). Myocardial bridging does not predict sudden death in children with hypertrophic cardiomyopathy but is associated with more severe cardiac disease - Reply. *Journal of American College of Cardiology* 38, 922-922.
19. Simons-Morton DG, Morgan T, Haskell W, King A, Applegate W, Blair S, Albright C, Cohen S, Ribisl P, O’Toole M, **Shih J**. Effects of physical activity counseling in primary care – The activity counseling trial: A randomized controlled trial. *Journal of American Medical Association* 286: 677-687, 2001.
20. Albert, PS., McShane, LM, **Shih, JH** and the U.S. National Cancer Institute Bladder Tumor Marker Network. Latent modeling approaches for assessing diagnostic error in P53 immunohistochemical assays in bladder cancer without a gold standard. *Biometrics* 57: 610-619, 2001.
21. Proschan, MA, McMahon, RP, **Shih, JH**, Hunsberger, SA, Geller, NL, Wittes, J, Knatterud, G. Statistical properties of the Wittes, Lakatos, and Probstfield imputation method in clinical trials. *Journal of Statistical Planning and Inference* 96: 155-165, 2001.

22. Chatterjee, N, **Shih, JH**. A bivariate mixture model for modeling familial association in diseases. *Biometrics* 57: 779-786, 2001.
23. **Shih, JH**. An Introduction to survival analysis. *Principles and practice of clinical research*, Gallin, J.I. (editor), 259-266, 2002.
24. **Shih, JH** and Chatterjee, N. Survival analysis of family data from case- control studies. *Biometrics* 58: 502-509, 2002.
25. Vasselli, J, **Shih, JH**, Iyengar, SR, Maranchie, J, Riss, J, Worrell, R, Torres-Cabala, C, Tabios, R, Mariotti, A, Stearman, R, Merino, R, Walther, MW, Simon, R, Klausner, R, Linehan, WM. Predicting survival in patients with metastatic kidney cancer by gene expression profiling in the primary tumor. *Proceedings of National Academy of Sciences*, 100: 6958-6963, 2003.
26. Su, H, Hu, N, **Shih, J**, Hu, Y, Wang, O, Chuang, EY, Roth, MJ, Wang, C, Goldstein, AM, Ding, T, Dawsey, SM, Giffen, C, Emmert-Buck, MR., Taylor, PR. Gene expression in esophagea squamous cell carcinoma reveals highly consistent molecular profiles and is related to a family history of upper gastrointestinal cancer. *Cancer Research*, 63: 3872-3876, 2003.
27. **Shih, JH** and Fay, MP. A class of permutation tests for some two-sample survival data problems. *Contemporary biostatistical issues in clinical trials*, Geller, N. (editor), 141-160, 2003.
28. Dobbin, K, **Shih, JH** and Simon, R. Statistical design of reverse dye microarrays. *Bioinformatics* 19: 803-810, 2003.
29. Dobbin, K, **Shih, JH** and Simon, R. Questions and answers on design of dual-label microarrays for identifying differentially expressed genes. *Journal of the National Cancer Institute* 95: 1362-1369, 2003.
30. Albert, PS and **Shih, JH**. Modeling tumor growth with random onset. *Biometrics* 59: 897-906, 2003.
31. Chatterjee, N and **Shih, JH**. On use of bivariate survival models with cure fraction. *Biometrics* 59: 1184-1185, 2003.
32. McShane, LM, **Shih, JH** and Michalowska, AM. Statistical issues in the design and analysis of microarray studies in animal models. *Journal of Mammary Gland Biology and Neoplasia* 8 359-374, 2003.
33. Fukuoka, J, Fujii, T, **Shih, JH**, Dracheva, T, Hewitt, S, Travis, WD, Jen, J. Chromatin remodeling factors in non-small cell lung cancer, cellular location of BRM and coexpression with BRG1 are important prognostic indicators. *Clinical Cancer Research* 10: 4314-4324, 2004.
34. Desai, KV, Michalowska, A, Kondaiah P, Ward, JM, **Shih, JH**, and Green JE. Gene expression profiling identifies Pten as a candidate apoptosis mediator in androgen depleted rat ventral prostate. *Molecular Endocrinology* 18:2895-2907, 2004.
35. Donniger, H, Bonome, T, Radonovich, M, Pise-Massion, C, Brady, J, **Shih, JH**, Barrett, JC, and Birrer M. Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways. *Oncogene* 23: 8065-8077, 2004.
36. **Shih, JH**, Michalowska, AM, Dobbin, K, Ye, Y, Qiu TH, Green JE. Effects of pooling mRNA in microarray class comparisons. *Bioinformatics* 20: 3318-3325, 2004.
37. Dobbin, K, **Shih, JH** and Simon, R. Comment on "Evaluation of the gene specific dye bias in cDNA microarray experiments". *Bioinformatics* 21: 2803-2804, 2005.

38. Tsurutani, J, Fukuoka, J, Tsurutani, H, **Shih, JH**, Hewitt, SM, Jen, J and Dennis PA. Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in NSCLC tumors. *Journal of Clinical Oncology* 24:306-314, 2006.
39. Mayburd, AL, Martinez, A, Sackett, D, Liu, H, **Shih, JH**, Tauler, J, Avis, I, Mulshine, JL. Ingenuity network assisted transcription profiling: Identification of new pharmacological mechanism for MK886. *Clinical Cancer Research* 12: 1820-1827, 2006.
40. Chatterjee, N, Zeynep, K, **Shih, JH** and Gail, M. Case-control study with family history data: a combined approach of kin-cohort and case-control analysis. *Biometrics* 62: 36-48, 2006.
41. Wang, H, Owens, JO, **Shih, JH**, Li, M, Bonner, RF, Mushinski, JF. Histological staining method preparatory to laser capture microdissection significantly affects detection of mRNAs in microarray hybridization. *BMC Genomics* 7:97, 2005.
42. Lu, SE, **Shih, JH**. Case-cohort designs and analysis of clustered failure time data. *Biometrics* 62: 1138-1148, 2006.
43. Fukuoka J, Dracheva T, **Shih, JH**, Hewitt SM, Travis, WD, and Jen J. Desmoglein 3 as a prognostic indicator for pulmonary carcinoid tumors. *Human Pathology* 38:276-83, 2007.
44. Lusa, L, McShane, LM, Radmacher, MD, **Shih, JH**, Wright, GW, Simon, R. Appropriateness of some resampling-based inference procedures for assessing performance of prognostic classifiers derived from microarray data. *Statistics in Medicine* 26:1102-13, 2007.
45. Johnson, L and **Shih, JH**. An Introduction to survival analysis. *Principles and practice of clinical research 2nd edition*, Gallin, J.I. (editor): 259-266, 2007.
46. Chatterjee, N, Zeynep, K, **Shih, JH** and Gail, M. Rejoinder to the letter to editor from C. Begg. *Biometrics* 63: 965-966, 2007.
47. Park, ES, Lee, JS, Woo, HG, Zhan, F, **Shih, JH**, Shaughnessy, JD, Mushinski, JF. Heterologous Tissue Culture Expression Signature Predicts Human Breast Cancer Prognosis. *PLoS ONE* Jan 3;2:e145, 2007.
48. Deeb, KK, Michalowska, AM, Yoon, CY, Krummey, SM, Hoenerhoff, MJ, Kavanaugh, C, Li, MC, Demayo, FJ, Linnoila, I, Deng, CX, Lee, E YH, Medina, D, **Shih, JH**, Green, JE. An integrated cancer genetic network predicts aggressive human carcinomas with poor prognosis. *Cancer Research* 67:8065-80, 2007.
49. Shilo, K, Dracheva, T, Mani, H, Fukuoka, J, Sesterhenn, I, Chu, WS, **Shih, JH**, Jen, J, Travis, W, Franks, T. Alpha-methylacyl CoA Racemase (AMACR) in Pulmonary Adenocarcinoma, Squamous Cell Carcinoma and Neuroendocrine Tumors: Expression and Survival Analysis. *Archives of Pathology & Laboratory Medicine* 31:1555-60, 2007.
50. Tang B, Yoo, N, Vu, M, Mamura, M, Nam, J, Ooshima, A, Desprez, P, Anver, M, **Shih, JH**, Parks, T, Wakefield, LM. TGF- α can function as a tumor suppressor in breast cancer through effects on the cancer stem cell and committed progeny that are independent of its antiproliferative activity. *Cancer Research* 67:8643-52, 2007.
51. **Shih, JH** and Lu, SE. Analysis of failure time data with multi-level clustering, with application to the child vitamin A intervention trial in Nepal. *Biometrics* 63:673-80, 2007.
52. **Shih, JH**. Sample size considerations for morbidity/mortality trials. *Wiley Encyclopedia of Clinical Trials* DOI: 10.1002/9780471462422, 2008.

53. Fenton, JI, Lavigne, LA, Perkins, SN, Liu, H, Chandramouli, G, **Shih, JH**, Hord, NG, Hursting, SD. Microarray analysis reveals that leptin induces autocrine/paracrine cascades to promote survival and proliferation of colon epithelial cells in an Apc genotype dependent fashion. *Molecular Carcinogenesis* 47: 9-21, 2008.
54. Landi, MT, Dracheva, T, Rotunno, M, Figueroa, JD, Liu, H, Dasgupta, A, Mann, F, Fukuoka, J, Hames, M, Bergen, A, Murphy, SE, Yang, P, Pesatori, AC, Consonni, D, Bertazzi, PA, Wacholder, S, **Shih, JH**, Caporaso, N, Jen, J. Gene expression signature of cigarette smoking and its role in lung adenocarcinoma risk and survival . *PLoS ONE* 3(2):e1651, 2008.
55. Bonome, T, Levine, DA, **Shih, JH**, Randonovich, M, Pise-Masison, CA, Brady, J, Barrett, JC, Boyd, J, Birrer, MJ. Identification of a gene signature predicting for survival in sub-optimally debulked patients with high-grade papillary serous ovarian cancer. *Cancer Research* 68:5478-5486, 2008.
56. Calvo, KR, Dabir, B, Kovach, A, Devor, C, Bandle, R, Bond, A, **Shih, JH**, Jaffe, ES. IL-4 protein expression and basal activation of Erk *in vivo* in follicular Lymphoma. *Blood* 112: 3818-3826, 2008.
57. Orina, JN, Calcagno, AM, Wu, CP, Varma, S, **Shih, JH**, Lin, M, Eichler, G, Weinstein, JN, Pommier, Y, Ambudkar, SV, Gottesman, MM and Gillet, JP. Generation of an improved drug discovery repository using high-throughput Taqman low density arrays. *Mol Cancer Ther* 8:2057-66, 2009.
58. **Shih, JH**, Lu, SE. Semiparametric estimation of a nested random effects model for the analysis of multi-level clustered failure time data. *Journal of Computation Statistics and Data Analysis* 53:3864-71, 2009.
59. Albert, PS, **Shih, JH**. On estimating the relationship between longitudinal measurements and time-to-event data using a simple two-stage procedure. *Biometrics* 66, 983-87, 2010.
60. Albert, PS, **Shih, JH**. An approach for jointly modeling multivariate longitudinal measurements and time-to-event data. *The Annals of Applied Statistics* 4,1517-1532, 2010.
61. **Shih, JH**, Albert, PS. Modeling familial association of ages at onset of diseases in the presence of competing risk. *Biometrics* 66:1012-1023, 2010.
62. Tauler, J, Zudaire, E, Liu, H, **Shih, J**, Mulshine, JL. hnRNP A2/B1 modulates epithelial-mesenchymal transition in lung cancer cell lines. *Cancer Research* 70:7137-7147, 2010.
63. Turkbey, B, Shah, VP, Pang, X, Bernado, M, Xu, S, Kruecker, J, Locklin, J, Baccala, AA, Rastinehad, AR, Merino, MJ, **Shih, JH**, Wood, BJ, Pinto, PA, Choyke, PL. Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? *Radiology* 258:488-495, 2010.
64. Rastinehad, AR, Baccal, AA, Chung, PH, Proano, JM, Kruecker, J, Xu, S, Lockin, JK, Turkbey, B, **Shih, J**, Linehan, WM, Glossop, ND, Choyke, PL, Wood, BJ, Pinto, PA. D'Amico Risk Stratification Correlates with Degree of Suspicion of Prostate Cancer on Multi-Parametric Magnetic Resonance Imaging (MRI). *Journal of Urology* 185:815-820, 2011.
65. Steffen-Smith, EA, **Shih, JH**, Warren, KE (2010). Proton magnetic resonance spectroscopy predicts survival in children with diffuse intrinsic pontine glioma. *Journal Neuro-Oncology* 105:365-73, 2011.
66. Hipp, SJ, Steffen-Smith, EA, Hammoud, D, **Shih, JH**, Bent, R, Warren, KE. Predicting outcome of children with diffuse intrinsic pontine gliomas using multiparametric imaging. *Neuro-Oncology* 13,904-9, 2011.
67. Kreisl, TN, Zhang, W, Odia, Y, **Shih, J**, Butman, JA, Hammoud, D, Iwamoto, F, Su, J, Fine, HA. A Phase II Trial of Single Agent Bevacizumab in Patients with Recurrent Anaplastic Glioma. *Journal of Neuro-Oncology* 13:1143-50, 2011.

68. Turkbey B, Mani, H, Shah, VJ, Rastinehad, AR, Bernardo, M, Pohida, T, Pang, Y, Daar, D, Benjamin, C, McKinney, YL, Trivedi, H, Chua, C, Bratslavsky, G, **Shih, JH**, Linehan, WM, Merino, MJ, Choyke, PL, Pinto, PA. Multiparametric 3T prostate MR imaging to detect cancer: histopathologic correlation using prostatectomy specimens processed in customized MRI-based molds. *Journal of Urology* 186:1818-1824, 2011.
69. Fay, M, **Shih, JH**. Weighted logrank tests for interval censored data when assessment times depend on treatment. *Statistics in Medicine* 31: 3760-3762, 2012.
70. Shuch, B, Bratslavsky, G, **Shih, J**, Vourganti, S, Finley, D, Castor, B, Treat, E, Linehan, WM, Pantuck, AJ, Said, J, Beldegrun, AS. Impact of pathologic tumor characteristics in patients with sarcomatoid renal cell carcinoma. *British Journal of Urology* 109:1600-166, 2012.
71. Chen, J, Petrus, M, Bamford, R, **Shih, JH**, Morris, JC, Janik, JE, Waldmann, TA. Increased serum soluble interleukin-15 receptor alpha (sIL-15R α) levels in T cell large granular lymphocyte leukemia. *Blood* 119:137-43, 2012.
72. Simone, NL, Dan, T, **Shih, JH**, Smith, SL, Sciuto, L, Lita, E, Swain, SM, Danforth, D, Camphausen, K. Twenty-five year results in the treatment of early stage breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute randomized trial. *Breast Cancer Research and Treatment* 132:197-203, 2012.
73. Zhang, C, Elkahlon, AG, Robertson, M, Gills, JJ, Tsurutani, J, **Shih, JH**, Fukuoka, J, Hollander, C, Harris, CC, Travis, WD, Jen, J, Dennis, PA. Loss of cytoplasmic CDK1 predicts poor survival in human lung cancer and confers chemotherapeutic resistance. *Plos One* 6(8):e23849, 2011.
74. Rotunno, M, Hu, N, Su, H, Wang, C, Goldstein, AM, Bergen, AW, Consonni, D, Pesatori, AC, Bertazzi, PA, Wacholder, S, **Shih, JH**, Caporaso, NE, Taylor PR, Landi MT. A gene expression signature from peripheral whole blood for stage I lung adenocarcinoma. *Cancer Prevention Research* 4:1599-608, 2011.
75. Pinto, PA, Chung, PH, Rastinehad, AR, Baccala, AA, Kruecker, J, Benjamin, CJ, Xu, X, Yan, P, Kadoury, S, Chua, C, Locklin, JK, turkbey, B, **Shih, JH**, Gates, SP, Buckner, C, Bratslavsky, G, Linehan, WM, Glossop, ND, Choyke, PL, Wood, BJ. Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. *Journal of Urology* 186:1281-1285, 2011.
76. Yan, W, **Shih, J**, Rodriguez-Canales, J, Hipp, J, Player, A, Hu, N, Goldstein, AM, Taylor, PR, Emmert-Buck, MR, Erickson, HS. Identification of unique therapeutic targets in esophageal squamous cell carcinoma. *BMC Research Notes* doi: 10.1186/1756-0500-5-73, 2012.
77. Warren, KE, Bent, R, Wolters, PL, Prager, A, Hanson, R, Packer, R, **Shih, J**, Camphausen, K. A phase II study of pegylated interferon Alfa-2b (PET-Intron®) in children with diffuse intrinsic protine glioma. *Cancer* 118:3607-3613, 2012.
78. Kurdziel, KA, **Shih, JH**, Linderberg, ML, Apolo, AB, Mena, E, McKinney, Y, Turkbey, IB, Dahut, W, Gulley, JL, Madan, R, Landgren, O, Choyke, PL. The kinetics and reproducibility of 18F-sodium fluoride (NaF) using current PET camera technology. *J Nuclear Medicine* 53:1175-84, 2012.
79. Scott, JG, Bauchet, L, Fraum, TJ, Nayak, L, Cooper, AR, Reiner, AS, Chao, ST, Suh, JH, Vogelbaum, MA, Peerboom, DV, Zouaoui, SZ, Mathieu-Daude, H, Fabbro-Peray, P, Rigau, V, Taillandier, L, Abrey, LE, DeAngelis, LM, **Shih, JH**, Iwamoto, FM. Recursive partitioning analysis identifies prognostic groups for glioblastoma patients aged 70 years or older. *Cancer* 118:5596-600, 2012.
80. Yan, W, **Shih, JH**, Rodriguez-Canales, J, Tangera, MA, Diao, L, Hu, N, Goldstein, AM, Wang, J, Taylor, PR, Lippman, SM, Wistuba, II, Emmert-Buck, MR, Erickson, HS. Three-dimensional mRNA measurements reveal minimal heterogeneity in esophageal squamous cell carcinoma. *American Journal of Pathology* 182:529-39, 2013.

81. Ou, W, Delisle, J, Jacques, J, **Shih, J**, Price, G, Kuhn, JH, Wang, V, Verthelyi, D, Kaplan, G, Wilson, CA. Induction of ebolavirus cross-species immunity using retrovirus-like particles bearing the Ebola virus glycoprotein lacking the mucin-like domain. *Virology Journal* 9:32 doi:10.1186/1743-422X-9-3, 2013.
82. Milenic, D, Kwamena, B, Wong, K, **Shih, J**, Brechbiel, M. Evaluation of platinum chemotherapy in combination with HER2 targeted α -particle radiation. *Cancer Biotheo Radiopharm* 28:441-9, 2013.
83. Kreisl TN, McNeill KA, Sul, J, Iwamoto, FM, **Shih, J**, Fine, HA. A phase I/II trial of vandetanib for patients with recurrent malignant glioma. *Neuro Oncology* 14:1519-26, 2013.
84. Kreisl TN, Smith, P, Sul, J, Salgado, C, Iwamoto, FM, **Shih, JH**, Fine, HA. Continuous daily sunitinib for recurrent glioblastoma. *Journal of Neurooncology* 11:41-8, 2013.
85. **Shih, JH**. Copula models and analysis for multivariate failure time data. In Klein, J, Ibrahim, J, Scheike, T, Houwelingen, HV, editors, *Handbook of Survival Analysis* pp. 489-510, 2013.
86. Chen J, Pise-Masison CA, **Shih JH**, Morris JC, Janik JE, Conlon KC, Keating A, Waldmann TA. Markedly additive antitumor activity with the combination of a selective surviving suppressant YM155 and alemtuzumab in adult T-cell leukemia. *Blood* 121:2029-37, 2013.
87. Mena E, Lindenberg ML, Turkbey BI, **Shih J**, Logan J, Adler SS, Wong KJ, Wilson W, Choyke PL, Kurdziel KA. A pilot study of the value of ^{18}F -Fluoro-deoxy-thymidine PET/CT in predicting viable lymphoma in residual ^{18}F -FDG avid masses following completion of therapy. *Clinical Nuclear Medicine* 39:874-81, 2013.
88. **Shih, JH**, Albert PS, Mendola, P, Laughon, SK. Modeling the Type and Timing of Consecutive events: Application to Predicting Preterm Birth in Repeated Pregnancies. *Journal of the Royal Statistical Society, Series C*. (In press).
89. Albert, PS, **Shih, JH**. Modeling batched Gaussian longitudinal data subject to informative dropout. *Statistical Methods in Medical Research* 23: 203-217, 2014.
90. Odia, Y, **Shih, JH**, Kreisl, TN. Bevacizumab-related toxicities in patients with malignant gliomas. *Journal of Neuro-oncology* 120:431-440, 2014.
91. Turkbey B, Mena E, **Shih J**, Pinto PA, Merino MJ, Lindenberg ML, Bernardo M, McKinney YL, Adler S, Owenius R, Choyke PL, Kurdziel KA. Localized Prostate Cancer Detection with ^{18}F FACBC PET/CT: Comparison with MR Imaging and Histopathology. *Radiology* (In press).
92. Mena, E, Owenius, R, Turkbey, B, Sherry, R, Bratslavsky, G, Machol, S, Miller, MP, Somer, EJ, Lindenberg, L, Adler, S, **Shih, J**, Choyke, P, Kurdziel, K. [^{18}F]fluciclatide in the in vivo evaluation of human melanoma and renal tumors expressing $\alpha\beta$ 3 and α $\nu\beta$ 5 integrins. *European Journal Nuclear Medicine and Molecular Imaging* (In press).
93. McNeil BK, Sorbellini M, Grubb RL, Cecchi F, Athauda G, Apolo A, Cohen B, Giubellino A, Simpson H, Coleman J, Getzenberg RH, Netto GJ, **Shih J**, Linehan MW, Pinto PA, Bottaro DP. Urinary met level as a novel biomarker for urothelial carcinoma of the bladder. *Journal of Translational Medicine* (in press).
94. Grant, KB, Agrwal, HK, **Shih, JH**, Bernado M, Pang Y, Daar, D, Merino, MJ, Wood, B, Pinto, PA, Choyke, PL, Turkbey, B. Comparisons of calculated and acquired high b-value diffusion weighted imaging in prostate cancer. *Abdominal Imaging* (in press).

95. Kreisl, TN, Zhang, W, Kreisl, TN, Iwamoto F, Sul, J, **Shih, J**, Solomon, J, Butman Smith, P, Sul, J, Salgado, C, Fine, HA. Parametric response maps of positron emission tomography and dynamic contrast-enhanced MRI as early biomarkers of bevacizumab activity in recurrent glioblastoma. Submitted.
96. Berkowitz, JL, Janik, JE, Stewart, KM, Jaffe, ES, Stetler-Stevenson, M, **Shih, J**, Fleisher, TA, Turner, M, Urquhart, N, Wharfe, GH, Figg, WD, Peer, C, Goldman, CK, Waldmann, TA, Morris, JC. Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma. *Clinical Immunology*. (In press).
97. Steffen-Smith, EA, Sarlls, J, Pierpaoli, C, **Shih, J**, Bent RS, Walker, L, Warren KE. Effects of corticosteroids on diffusion tensor histogram analysis of children with diffuse intrinsic pontine glioma (DIPG). *BioMed Research International* doi: 10.1155/2014/647356, 2014.
98. Turkbey, B, Agarwal HK, **Shih, J**, Bernardo M, McKinney, YL, Daar, D, Griffiths, GL, Sankineni, S, Johnson, L, Grant, KB, Weaver, J, Rais-Bahrami, S, Harisinghani, M, Jacobs, P, Dahut, W, Merion, MJ, Pinto, PA, Choyke, PL. A phase I dosing study of ferumoxyl for magnetic resonance lymphography in patients with prostate cancer. *American Journal of Roentgenology* (in press).
99. Walton Diax, A, Truong, H, Siddiqui, MM, Miao, N, **Shih, JH**, Mannes, A, Bratslavsky, G, Linehan, WM, Metwalli, AR. Postoperative elevation in creatinine kinase has minimal impact on renal function in patients undergoing complex partial nephrectomy. Submitted.
100. Walton-Diaz, An, Shakir, N, Rais-Bahrami, S, Turkbey, B, George, AK, Rothwas, J, Stamatakis, L, Hong, CH, Siddiqui, MM, Okoro, C, Raskolnikov, D, Su, D, **Shih, J**, Han, H, Merion, MJ, Simon, R, Wood, BJ, Choyke, PL, Pinto, PA. Utility of multiparametric MRI in the management of prostate cancer patients on active surveillance. Submitted.
101. Krauze, AV, Myrehaug, SD, Chang, MG, Holdford, DJ, Smith, S, **Shih, J**, Tofilon, PJ, Fine, H, Camphausen, K. A phase II study of concurrent radiation therapy, temozolomide and the histone deacetylase inhibitor valproic acid for patients with glioblastoma multiforme. Submitted.
102. Muller, BG, **Shih, JH**, Sankineni, S, Marko, J, Rais-Bahrami, S, George, A, Rosette JJMHC dela, Merino, MJ, Wood, BJ, Pinto, P, Choyke, PL, Turkbey B. Inter-observer agreement and accuracy of the revised prostate imaging – reporting and data systems (PI-RADS) for interpreting multiparametric MRI of the prostate. Submitted.
103. Brown, AM, Lindenberg, ML, Sankineni, SS, **Shih, JH**, Johnson, LM, Pruthy, S, Kurdziel, KA, Merino, MJ, Wood BJ, Pinto, PA, Choyke, PL. Does focal incidental ¹⁸F-FDG PET/CT uptake in the prostate have significance? Submitted.

Invited Presentations in Profession Meetings and Seminars

1. Cigarette smoking and mortality: Data on 361,662 MRFIT primary screenees. Presentation at the National Cancer Institute planning meeting on Smoking and Tobacco Control Program monograph, 1991.
2. . Sample size calculation for complex clinical trials. University of Minnesota, 1992.
3. Models and analysis for multivariate failure time data. National Heart, Lung, and Blood Institute, 1992.
4. Models and analysis for multivariate failure time data. National Cancer Institute, 1992.
5. Models and analysis for multivariate failure time data. Department of Biostatistics, University of Washington, 1992.

6. Models and analysis for multivariate failure time data. Division of Biostatistics, University of Rochester, New York, 1992.
7. Models and analysis of multivariate failure time data. Henry Ford Hospital, Michigan, 1992.
8. Models and analysis for multivariate failure time data. Department of Biostatistics, University of Michigan, 1992
9. Models and analysis for multivariate failure time data. Department of Biostatistics, University of North Carolina, 1992.
10. Models and analysis for multivariate failure time data, Pennsylvania State University, Medical School, 1992.
11. Models and analysis for multivariate failure time data. Wake Forest University, Bowman Gray school of Medicine, 1992.
12. Models and analysis for multivariate failure time data. University of Pennsylvania, Medical school, 1992.
13. Tests of independence of bivariate failure time data, National Heart, Lung, and Blood Institute, 1992.
14. A goodness-of-fit test for association in a bivariate survival model, International Chinese Statistical Association Symposium, 1996.
15. Modeling multivariate discrete failure time data, National Cancer Institute, 1998.
16. Modeling multivariate discrete failure time data, Department of Biostatistics, Johns Hopkins University, 1998.
17. A class of permutation tests for stratified survival data. International Chinese Statistical Association (ICSA) annual meeting, Washington, D.C., 1999.
18. Latent models for correlated binary data with diagnostic error. Joint Statistical Meetings, Baltimore, MD, 1999.
19. A cure model for bivariate failure time data. Department of Biostatistics, Columbia University, New York, 2000.
20. Sample size calculation for complex clinical trials with survival endpoints, Pfizer Cooperation, Connecticut, 2001.
21. Design and Analysis issues in the microarray studies of animal models, Mouse Models of Mammary Cancers Retreat, Gaithersberg, MD, 2003.
22. Design, analysis and interpretation of microarray gene expression data (II), National Institute of Child Health and Development, 2003.
23. Design, analysis and interpretation of microarray gene expression data (I), National Institute of Child Health and Development, 2003
24. A bivariate cure-mixture approach for modeling familial association in diseases, Joint Statistical Meetings, San Francisco, 2003.
25. Analysis of survival data from case-control family studies. Johns Hopkins University, Department of Biostatistics, 2003.
26. Estimating relative risk, cumulative risk and familial aggregation from case-control designs with genotype and family history data, University of Medicine and Dentistry of New Jersey, Department of Biostatistics, 2004.

27. Effects of pooling mRNA in microarray class comparisons. Lombard Comprehensive Cancer Center, Georgetown University, 2005.
28. Effects of pooling mRNA in microarray class comparisons. International Chinese Statistical Association Annual Meeting, 2005.
29. Analysis of failure time data with multi-level clustering, with application to the child intervention trial in Nepal. ENAR, Tampa, Florida, 2006.
30. Analysis of failure time data with multi-level clustering, with application to the child intervention trial in Nepal. Division of Biostatistics, Albert Einstein College of Medicine of Yeshiva University, Spring 2007.
31. Semiparametric approaches for the analysis of multi-level failure time data. University of Maryland Cancer Center, Spring 2007.
32. Semiparametric approaches for the analysis of multi-level failure time data. Joint Statistical Meetings, Salt Lake City, Utah, 2007.
33. Modelling familial association of ages of onset of disease in the presence of competing risk. Joint Statistical Meetings, Colorado, 2008
34. Modelling familial association of ages of onset of disease in the presence of competing risk. National Heart, Lung, and Blood Institute, 2008.
35. Modelling familial association of ages of onset of disease in the presence of competing risk., Queen's University, Canada, September, 2009.
36. Modelling familial association of ages of onset of disease in the presence of competing risk, University of Pennsylvania, October, 2010.
37. Modelling familial association of ages of onset of disease in the presence of competing risk. National Institute of Child Health and Human Development, 2011.
38. Discussant of Byar Award Sessions, Joint Statistical Meetings, San Diego, California, 2012.
39. Modeling the type and timing of consecutive events: application to predicting preterm birth in repeated pregnancies, Joint Statistical Meetings, Boston, Massachusetts, 2014

Contributed Talks in Statistical Meetings

1. Models and analysis for multivariate failure time data, Eastern North American Region International Biometric Society (ENAR) Meeting, Houston, Texas, 1992.
2. Tests of independence for bivariate failure time data, Eastern North American Region International Biometric Society (ENAR) Meeting, Cleveland, Ohio, 1994.
3. Assessing gamma frailty models for clustered failure time data, Lifetime Data: Models in Reliability and Survival Analysis Symposium, Boston, Massachusetts., 1995.

4. Modeling multivariate discrete failure time data, Eastern North American Region International Biometric Society (ENAR) Meeting, Richmond, Virginia, 1996.
5. A goodness-of-fit test for association in a bivariate survival model, Eastern North American Region International Biometric Society (ENAR) Meeting, Memphis, Tennessee, 1997.
6. Latent models for correlated binary data with diagnostic error, Eastern North American Region International Biometric Society (ENAR) Meeting, Pittsburgh, Pennsylvania, 1998..
7. A class of permutation tests for stratified failure time data, Eastern North American Region International Biometric Society (ENAR) Meeting, Atlanta, Georgia, 1999.
8. Effects of pooling mRNA in microarray class comparions, Joint Statistical Meetings, Toronto, Canada, 2004.